Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.39 |
| ▸ | FLT3 | P36888 | 5/20 | 0.39 |
| ▸ | KIT | P10721 | 3/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 2/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.35 |
| ▸ | PRKACA | P17612 | 2/20 | 0.35 |
| ▸ | LTK | P29376 | 2/20 | 0.35 |
| ▸ | GRK5 | P34947 | 2/20 | 0.35 |
| ▸ | CDK8 | P49336 | 2/20 | 0.35 |
| ▸ | CDK7 | P50613 | 2/20 | 0.35 |
| ▸ | CDK9 | P50750 | 2/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.35 |
| ▸ | MST1R | Q04912 | 2/20 | 0.35 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4590437 | 0.76 | BRD4 (0.33) | — | |
| SCHEMBL405423 | 0.76 | — | — | |
| SCHEMBL9588423 | 0.72 | — | — | |
| SCHEMBL9589093 | 0.72 | CA12 (0.33) | — | |
| SCHEMBL2565476 | 0.69 | IDO1 (0.37) | LIMK1GSK3B | |
| SCHEMBL9590317 | 0.69 | FAAH (0.32) | — | |
| SCHEMBL52685 | 0.66 | CA12 (0.48) | KDRFLT3KITAURKBMAP4K4 | |
| SCHEMBL3091506 | 0.65 | NPC1 (0.40) | — | |
| SCHEMBL2445430 | 0.63 | KDR (0.58) | KDRFLT3KITAURKBMAP4K4 | |
| Hydrochloric Acid SCHEMBL5103456 | 0.61 | KDR (0.56) | KDRFLT3KITAURKBMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613319-B1 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2009-06-03 | — | — | EP | claimed |
| JP-2006522809-A | — | — | 2006-10-05 | — | — | JP | claimed |
| EP-1613319-A2 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-01-11 | — | — | EP | claimed |
| US-20040254166-A1 | Substituted phenyl acetamides and their use as protease inhibitors | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C. | 2004-12-16 | — | — | US | claimed |
| WO-2004091613-A2 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | claimed |
| EP-2373634-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8642582-B2 | Morpholinone compounds as factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2373634-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | Mochida Pharmaceutical Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | disclosed |
| WO-2010065717-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-06-10 | — | — | WO | disclosed |
| US-7550474-B2 | Substituted phenyl acetamides and their use as protease inhibitors | JOHNSON & JOHNSON PHARMACEUTICALS RESEARCH & DEVELOPMENT, L.L.C. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1613319-B1 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1613319-A2 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20040254166-A1 | Substituted phenyl acetamides and their use as protease inhibitors | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C. | 2004-12-16 | — | — | US | disclosed |
| WO-2004091613-A2 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | KDR 2062/4885FLT3 1068/4885KIT 2207/4885 |
| US-20040254166-A1 | Substituted phenyl acetamides and their use as protease inhibitors | TFPI, F12, SPINT2 | KDR 2010/4885FLT3 958/4885KIT 1151/4885 |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | KDR 2062/4885FLT3 1068/4885KIT 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.